Abstract 425P
Background
Palonosetron (PALO) is a second-generation 5-hydroxytryptamine 3 receptor antagonist (5HT3RA) that has shown better efficacy than first-generation 5HT3RA (granisetron; GRA) in preventing chemotherapy-induced nausea and vomiting (CINV). PALO is usually administrated repeatedly when the patients have no nausea even though it is expensive as compared with GRA. However, we could reduce medical costs for chemotherapy if 5HT3RA conversion from PALO to GRA in the patient without having CINV is safe and tolerable.
Methods
We prospectively investigated patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC) in combination with PALO for digestive organ cancers in accordance with guideline of Japan Society of Clinical Oncology. Patients assessed as complete response (CR) during the acute phase (0-24 h postchemotherapy) and the delayed phase (24-120 h postchemotherapy) in consecutive treatments were converted their antiemetic agents from PALO to GRA. We evaluated the incidence of CINV and the cost-effectiveness.
Results
Thirty five cases (madian age 73 years, female 51.4%, 18; pancreatic cancer, 8; colorectal cancer, 3; esophageal cancer, 3; gastric cancer, 3; biliary tract cancer) were enrolled at our institution between January 2018 and June 2019. Ten cases were administrated HEC (HEC group) and 25 cases were administrated MEC (MEC group). One case of HEC group and 2 cases of MEC group changed their chemotherapy regimens due to adverse events and progression of disease. Four cases of HEC group (40.0%) and 14 cases of MEC group (56.0%) were assessed as CR in consecutive treatments, thereafter their antiemetic agents were converted from PALO to GRA in the subsequent treatments. All of them continued their chemotherapy without the incidence of nausea and vomiting. Among the cases assessed as CR, we could save 111,935 Japanese yen (1,034.6 USD, range, 13,868-194,152 JPY) per case by conversion of 5HT3RA.
Conclusions
Our data indicated that the conversion of 5HT3RA is safe and also provide economic benefit in patients receiving HEC or MEC. When patients receiving HEC or MEC with PALO were assessed as CR, we should consider conversion of 5HT3RA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asahikawa medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract